CA Patent

CA2963931A1 — Anti-tnf compounds

Assigned to Exicure Inc · Expires 2016-04-14 · 10y expired

What this patent protects

TNFa antisense oligonucleotides are provided herein. Methods of treating TNFa diseases or disorders using the TNFa antisense oligonucleotides and related products are provided.

USPTO Abstract

TNFa antisense oligonucleotides are provided herein. Methods of treating TNFa diseases or disorders using the TNFa antisense oligonucleotides and related products are provided.

Drugs covered by this patent

berdazimer-sodium (BERDAZIMER SODIUM)

Patent Metadata

Patent number: CA2963931A1
Jurisdiction: CA
Classification: —
Expires: 2016-04-14
Drug substance claim: No
Drug product claim: No
Assignee: Exicure Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.